Search Results
Found 2 results
510(k) Data Aggregation
(142 days)
ORIGIO® Sequential Fert™ is for the fertilization of oocytes in vitro.
ORIGIO® Sequential Cleav™ is for the culture of embryos until the 2-8 cell stage. ORIGIO® Sequential Cleav™ can also be used for embryo transfer at day 2 or 3.
ORIGIO® Sequential Fert™ and ORIGIO® Sequential Cleav™ are aseptically filtered, non viscous solutions, light pink or colorless solutions, which are ready to use by professionals within assisted reproduction.
ORIGIO® Sequential Fert™ and ORIGIO® Sequential Cleav™ are contained in 10 mL or 60 mL transparent polyethylene terephthalate glycol (PETG) bottles with high density polyethylene (HDPE) closures, available in card board boxes of 1 x 10 mL and 1 x 60 mL bottles. The bottles and boxes are individually labeled. The boxes also contain instruction for use provided as package insert.
This document describes the ORIGIO® Sequential Fert™ and ORIGIO® Sequential Cleav™ medical devices. The submission focuses on demonstrating substantial equivalence to predicate devices rather than proving the device meets acceptance criteria from a standalone clinical study.
Therefore, a table of "acceptance criteria" and "reported device performance" specifically for the device's diagnostic performance (like sensitivity/specificity) is not provided in the typical sense of a diagnostic medical device. Instead, the "acceptance criteria" are implied by the comparison to predicate devices' specifications and functional properties through various laboratory tests.
Here's an analysis of the provided information:
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria are generally expressed as ranges or thresholds for various physicochemical properties and biological performance in comparison to predicate devices and recognized ART media. The reported device performance is stated to meet these specifications.
| Characteristic | Acceptance Criteria (ORIGIO® Sequential Fert™) | Reported Device Performance (ORIGIO® Sequential Fert™) | Acceptance Criteria (ORIGIO® Sequential Cleav™) | Reported Device Performance (ORIGIO® Sequential Cleav™) |
|---|---|---|---|---|
| pH | 7.3-7.5 | Meets specification (implied) | 7.2-7.4 | Meets specification (implied) |
| Osmolality (mOsm/kg) | 277-293 | Meets specification (implied) | 272-288 | Meets specification (implied) |
| Endotoxin (EU/mL) | <0.15 | Meets specification (implied, better than predicate) | <0.15 | Meets specification (implied, better than predicate) |
| Aseptically filtered | X | Meets specification (implied) | X | Meets specification (implied) |
| 1-cell MEA (Mouse Embryo Assay) | ≥80% | ≥80% | ≥80% | ≥80% |
| Sterility | Sterile | Meets specification (implied) | Sterile | Meets specification (implied) |
| HSA Concentration | Stable through shelf life | Meets specification (implied) | Stable through shelf life | Meets specification (implied) |
| Biocompatibility | Cytotoxicity, sensitization, and irritation tests demonstrate biocompatibility (for ORIGIO® Sequential Cleav™ only) | Biocompatible (for short duration contact with mucosal tissues) | N/A | N/A |
| Shelf Life | 36 weeks | Validated to 36 weeks | 36 weeks | Validated to 36 weeks |
Note: The document does not provide specific numerical "reported device performance" results for pH, osmolality, endotoxin, or sterility, but states that these parameters were tested and met specifications or were comparable to predicate devices. For MEA, the specific percentage is given as >=80% in the table, implying this was maintained.
2. Sample size used for the test set and the data provenance
The document does not describe a clinical "test set" in the context of diagnostic device performance (e.g., patient data for sensitivity/specificity). Instead, the "testing" refers primarily to:
- Physicochemical analyses: pH, osmolality, endotoxin, sterility performed on batches of the manufactured media. The sample size for these manufacturing release tests is not specified but would typically follow internal quality control procedures.
- Mouse Embryo Assay (MEA): This is a biological test performed on mouse embryos to assess the media's ability to support embryo development. The sample size for MEA is stated as achieving "≥80%," indicating a pass/fail criterion rather than a detailed study sample size. The provenance of these mouse embryos or the exact number tested is not detailed.
- Stability Studies: Conducted to determine shelf life, testing pH, osmolality, endotoxin, HSA concentration, MEA, and sterility over time. The sample size (number of batches, number of samples per batch/time point) for these studies is not specified.
- Biocompatibility Testing: Performed for ORIGIO® Sequential Cleav™. This involves standardized in vitro and in vivo tests (cytotoxicity, sensitization, irritation). The sample size for these specific tests is not provided, but generally involves a predetermined number of test samples.
All data described appears to be retrospective (part of product development and qualification) and is generated by ORIGIO a/s (Denmark) or contracted laboratories.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
N/A. This product is an in vitro fertilization (IVF) medium, not a diagnostic device that requires expert ground truth for interpretation of discrete outputs. The "ground truth" for its performance is assessed through its physical and chemical properties and its ability to support embryo development (MEA), which are objective laboratory measurements, not subjective expert interpretations.
4. Adjudication method (e.g., 2+1, 3+1, none) for the test set
N/A. As this is not a diagnostic device or a study involving human interpretation, an adjudication method for a "test set" is not applicable.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
N/A. No MRMC study was conducted. This device is an IVF medium, not an AI or imaging device involving human readers.
6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done
N/A. There is no algorithm or AI component to this device.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
The "ground truth" for this product's performance is established by:
- Physicochemical standards: pH, osmolality, endotoxin levels are measured against predefined acceptable ranges.
- Biological performance standards: The Mouse Embryo Assay (MEA) serves as a biological ground truth, where successful development of mouse embryos (≥80% 1-cell MEA) indicates the medium's suitability.
- Comparison to predicate devices: The "ground truth" for substantial equivalence is met by demonstrating that the new devices have comparable technological characteristics and performance to legally marketed predicate devices.
8. The sample size for the training set
N/A. This is not a machine learning or AI device, so there is no training set in that context. The "training" in product development refers to formulation optimization and initial testing, but no specific "training set" of data is mentioned.
9. How the ground truth for the training set was established
N/A. See above.
Ask a specific question about this device
(175 days)
ORIGIO® Sequential Blast™ is for the culture of embryos from the 4-8 cell stage through to the blastocyst stage. ORIGIO® Sequential Blast™ can also be used for embryo transfer.
ORIGIO® Sequential Blast™ (with and without phenol red) is intended for the culture of human embryos from the 4-8 cell stage through to the blastocyst stage and for embryo transfer.
Two versions of ORIGIO® Sequential Blast™ are available:
- Catalogue no. 8305: ORIGIO® Sequential Blast™ .
- . Catalogue no. 8306: ORIGIO® Sequential Blast™ with phenol red
Both versions of ORIGIO® Sequential Blast™ are aseptically filtered, non viscous solutions, light pink or colorless solutions, which are ready to use by professionals within assisted reproduction.
The ORIGIO® Sequential Blast™ media are contained in 10 mL or 60 mL transparent polyethylene terephthalate glycol (PETG) bottles with high density polyethylene (HDPE) closures, available in card board boxes of 1 x 10 mL and 1 x 60 mL bottles. The bottles and boxes are individually labeled. The boxes also contain instruction for use provided as package insert.
The provided document is a 510(k) summary for ORIGIO® Sequential Blast™ and ORIGIO® Sequential Blast™ with phenol red, a reproductive media for culturing human embryos. It focuses on demonstrating substantial equivalence to a predicate device, BlastAssist® (K080172), rather than presenting a study to prove acceptance criteria for a device involving AI or human-in-the-loop performance. Therefore, many of the requested elements are not applicable to this type of submission.
However, I can extract the relevant information regarding acceptance criteria and performance data for this specific medical device (embryo culture media):
1. A table of acceptance criteria and the reported device performance
The document provides a comparison of product specifications between the proposed device (ORIGIO® Sequential Blast™) and the predicate device (BlastAssist®), which serve as the de-facto acceptance criteria for demonstrating substantial equivalence. The reported device performance is indicated by its ability to meet these comparable specifications.
| Product Specification | Proposed Device (ORIGIO® Sequential Blast™) | Predicate Device (BlastAssist®) |
|---|---|---|
| pH | 7.2-7.5 | 7.3-7.5 |
| Osmolality (mOsm/kg) | 272-288 | 272-288 |
| Endotoxin (EU/mL) | <0.15 | ≤0.1 |
| Sterility | No growth | No growth |
| 1-cell MEA | ≥80% | ≥80% |
2. Sample size used for the test set and the data provenance
The document describes "stability studies" and "Mouse Embryo Assay (MEA) test" as part of the performance data. However, it does not explicitly state the sample size for these tests or the data provenance (e.g., country of origin, retrospective/prospective).
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
This information is not applicable as the device is an embryo culture medium, not an AI or diagnostic device requiring expert interpretation of results for ground truth establishment.
4. Adjudication method for the test set
This information is not applicable for the same reason as point 3.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
This information is not applicable as the device is not an AI or diagnostic device that would involve human readers.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
This information is not applicable as the device is not an algorithm or AI system.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
For this type of device, the "ground truth" or validation is based on:
- Physicochemical properties: Meeting specified pH, osmolality, and endotoxin limits.
- Sterility: Absence of microbial growth.
- Biological performance: Mouse Embryo Assay (MEA) demonstrating proper embryonic development (≥80% 1-cell MEA).
- Stability studies: Showing the product maintains its specifications over its shelf life.
8. The sample size for the training set
This information is not applicable as the device is not an AI or machine learning system that requires a "training set."
9. How the ground truth for the training set was established
This information is not applicable for the same reason as point 8.
Ask a specific question about this device
Page 1 of 1